Hepatitis C Management in Special Populations
Summary
- The AASLD/IDSA (Management Guidelines)[AASLD-IDSA HCV] and EASL (Management Guidelines)[EASL HCV] guideline panels provide recommendations for the use of DAA regimens in the treatment of HCV infection in patients with recurrent HCV infection in posttransplantation settings (Table 12)
- Drug–drug interactions between HCV therapies and immunosuppressants commonly prescribed in the posttransplantation setting may occur (Table 13)
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content